Cytosorbents Corp with TICKER NASDAQ:CTSO has had its stock rating noted as ‘Reiterated’ with the recommendation being set at ‘BUY’ this morning by analysts at MLV & Co. Cytosorbents Corp are listed in the Health Care sector within NASDAQ. MLV & Co have set their target price at 21 USD on its stock. This now indicates the analyst believes there is a potential upside of 195.4% from today’s opening price of 7.11 USD. Cytosorbents Corp NASDAQ:CTSO has a 50 day moving average of 10.12 USD and the 200 Day Moving Average price is recorded at 7.93 USD. The 1 year high for the share price is 15.24 USD while the year low stock price is currently 4.4 USD.
Cytosorbents Corp NASDAQ:CTSO is a development stage critical care focused immunotherapy company using blood purification to modulate inflammation to preventing or treating multiple organ failure in life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids. In addition to CytoSorb, the Company is developing other products utilizing its adsorbent polymer technology that have not received regulatory approval including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.